AbbreviationDefinition
*P<.05
**P<.01
***P<.001
AAmplitude
AA (20:4 n-6)Arachidonic acid
AcActivation parameter
ACIntra-atrial conduction time
AHRQAgency for Healthcare Research and Quality
AIAdequate Intake
ALA (18:3 n-3)Alpha-linolenic acid
AmbAmbient
AP or APRAction potential rate
APAAction-potential amplitude
APD40 Action-potential duration at 40% depolarization
APD80 Action-potential duration at 80% depolarization
ApoApoprotein
APSActive pump sites
APTAction potential threshold
ARArrhythmia
ARArAreas at risk of arrhythmias
ARPFunctional refractory period of the atrium
ASArrhythmia scores
ASCAsynchronous contraction
ATPAdenosine triphosphate
ATPaseAdenosine triphosphatase
AVCAtrioventricular conductance time
AVRPFunctional refractory period of atrio-ventricular conducting system
BBasal
BBlocked (when used with arrythmias)
BAYBay K8644
BEPBasal electromechanical parameters
Bmax High and low affinity binding sites
BMIBody mass index
BPBlood pressure
BSABovine serum albumin
BTBenzonthiazepine calcium current-voltage (ICa-V) curves
BUMEBumetamide
BWLipoxygenase inhibitor
C20 Contraction coupling delay (ms)
CaCalcium
Ca2+ Calcium
CABCommonwealth Agricultural Bureau
cAMPCyclic adenosine monophosphate
CAFFCaffeine
CaFluCalcium intermittent fluctuations
CCTRCochrane Central Register of Controlled Trials
CD20 Contraction duration at 20% relaxation (ms)
CD80 Contraction duration at 80% relaxation (ms)
CICRCalcium induced contractile response
CLCell Length
CLOCod liver Oil
+CmaxCell shortening velocity
-Cmax Relaxation time
COCorn Oil
ContraContractility or beating rate (beats/min)
COXCyclo-oxygenase
CPcontractile parameters
CSF IIContinuing Food Survey of Intakes by Individuals 1994-1998
CRPC reactive protein
CtrlControl
CVDCardiovascular disease
CysCytosolic
DDietary supplement company (in evidence table)
DDuration (in summary table)
DDecreased (when in footnote of table)
dBcAMPDibutyryl cyclic adenosine monophosphate
DBHQ2,4-Di-tert-butylhydroquinone
DCLDiastolic cell length
DDDose dependent
Dep APTDepolarizing action potential threshold
df/dtMaximum rate of rise of contraction
-df/dtMaximum rate of rise of relaxation
DHA (22:6 n-3)Decosahexaenoic acid
DHAeDHA esters
DHPA3H-dihydroalprenolol
DiaDiastolic
DILDiltiazem
DLDiastolic length
DMDiabetes mellitus
DPA (22:5 n-3 or n-6)Docosapentaenoic acid
DRIDietary References Intakes
DTSDense tubular system
DXRDoxorubicin
EAElectrical automaticity/excitability
EAREstimated Average Requirement
ECGElectrocardiogram
EC50That concentration needed to produce a 50% effect
e.e.ethylated
EFAEssential fatty acid
endoendocardial
EPA (20:5 n-3)Eicosapentaenoic acid
EPA-eEPA esters
EPCEvidence-based Practice Center
Epiepicardial
ET-1Endothelin-1
ETYAEicosatetraynoic acid
FFrequency
FACFatty acid composition
FDAFood and Drug Administration
FOFish Oil
FOCForce of contraction
FRGSFree radical generating system
FVRForce-velocity relationship (Vmax, initial muscle length, maximum extent of twitch muscle shortening, time to peak shortening, positive peak of the normalized force derivative of the fully isometric twitch, total isometric force normalized per cross-sectional area, time to peak force)
GGovernment
GLA (18:3 n-6)Gamma linolenic acid
HCHigh Cholesterol
HDLHigh density lipoprotein
HFHigh fat
HTNHypertension
Hy RMPHyperpolarizing
IIndustry
IIncreased (when in footnote of table)
ICa.L Voltage dependent L-type Ca2+ current/inward Ca2+ current/Ca2+ sparks
ICa-VCalcium current-voltage
ICHIon channel
ICl.Ca Caffeine and Neurokinin A elicited Ca2+ dependent Cl- current
ICUIon currents
IC50That concentration that produces a 50% reduction in the effect
IK Delayed rectifier K+ current
IKI Inward rectifier K+ current or tail current
IKUR Ultra rapid potassium current
ILInterleukin
InAcInactivation parameter
InIonomycin
INa Sodium current
INDOIndomethacin
InsPInositol phosphate
IOMInstitute of Medicine
IPInotropic Parameters
IPIM- Ion pumps and ion movement
ISInfarct size
ISOIsoproteronol;
ISUS Outward K+ current
Ito Transient K+ outward current or initial outward current
K+ Potassium
KClPotassium chloride
KdAffinity
KRBKrebs Ringer bicarbonate
LMembrane leakiness
LResting cell length (inotropic measure in contractile parameter table)
LA (18:2 n-6)Linoleic acid
LC PUFALong-chain polyunsaturated fatty acid
LDLactate dehydrogenase
LDLLow density lipoprotein
LINLinseed Oil
LPLipoprotein
LPClysophosphatidylcholine
LPSlipopolysaccharide
LTLeukotriene
LVHLeft ventricular hypertrophy
MagMagnitude
MAPMonophasic action potential duration
MDPMaximal diastolic potential
m.e.Methyl ester
MenOMenhaden oil
MEXMexiletine
MgMagnesium ATPase
MIMyocardial infarction
MOMitochondrial oligomycin sensitive ATPase
MPMetabolites and pathways
MUFAMonounsaturated fatty acit
NNon-government / non-profit
NaSodium
Na+ Sodium
NANot available
NadSodium dependent
Na/KSodium potassium
NBNo blocks
NCNo change
Na/H exchSodium/hydrogen exchanger
NCHSNational Center for Health Statistics
NDNo data
NDGANordihydroguiarectic acid
NEMCNew England Medical Center
NEUNeurokinin
NHANES IIINational Health and Nutrition Examination 1988-1994
NIHNational Institutes of Health
NITNitrendipine
NorEpiNorepinephrine
NPNot for Profit
OOther (in evidence table)
O2Oxygen
ODSOffice of Dietary Supplements
OOOlive Oil
OSovershoot potential
OUAOuabain
OvAIovalbumin
PPrevented (when in footnote of table)
PAAPhenylalkylamine
PAIPlasminogen activator inhibitor
PasPassive
PCLPercent cell length
PE/APump efficiency or affinity for ATP
PGProstaglandin
PHEPhenylephrine
PIRPoverty Income Ratio
PLC-bReceptor mediated phospholipase C
PPARPeroxisome proliferator activated receptor
PRPPost rest potentiation
PTCPalmitoylcarnitine
PUFAPolyunsaturated fatty acid
QRSVentricular conductance time
QtElectrocardiogram interval
RCLResting cell length
RDARecommended Dietary Allowances
RDTResting/developed tension
ReOxyReoxygenation
RORapeseed oil (canola oil)
RPResting potential
RRPRelative refractory period
RSERelative standard error
SAFSafflower Oil
SCSpontaneous contraction
SCLSystolic cell length
SC-RANDSouthern California-RAND
SDStandard deviation
SEMStandard error of the mean
SFSaturated fat
SFASaturated fatty acid
SLSarcolemma
SM3Synthesized medium for omega-3 group
SM6Synthesized medium for omega-6 group
SRSarcoplasmic reticulum
SREBPSterol regulatory element binding protein
STA or STDStandard
SUPSupplement
SysSystolic
TTerminated (when in footnote of table)
TATwitch amplitude
TCTotal cholesterol
tC20 Contracting coupling delay
TDTime dependent
TEPTechnical Expert Panel
TgTriglycerides
TICTime constant of Ito inactivation
TIMTimolol
TNFTumor necrosis factor
TPATissue plasminogen activator
TSTwitch size
TSRTime in sinus rhythm
TT FATotal Fatty Acids
TxThromboxane
UOUniversity of Ottawa
USDAUnited States Department of Agriculture
VCAMVascular cell adhesion molecule
VEBVentricular ectopic beats
VENVentricular
VERVerapamil
VERPLeft ventricular effective refractory period
VFVentricular fibrillation
VFTVentricular fibrillation threshold
VLDLVery low density lipoprotein
VLN-3FAVery long chain n-3 fatty acid
Vmax Maximum rate of depolarization
VPVasopressin
VPBVentricular premature beat
VSVelocity of shortening
VSRMVoltage-sensitive release mechanism
VTVentricular tachycardia
W/WWeight-by-weight

From: List of Acronyms, Abbreviations, and Parameters

Cover of Effects of Omega-3 Fatty Acids on Arrhythmogenic Mechanisms in Animal and Isolated Organ/Cell Culture Studies
Effects of Omega-3 Fatty Acids on Arrhythmogenic Mechanisms in Animal and Isolated Organ/Cell Culture Studies.
Evidence Reports/Technology Assessments, No. 92.
Jordan H, Matthan N, Chung M, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.